Plasma concentrations of enrofloxacin and its active metabolite ciprofloxacin in dogs following single oral administration of enrofloxacin at 7.5, 10, or 20 mg/kg

Veterinary Therapeutics

Volumn 3, Issue 4, 2002, Pages

  Boothe, Dawn Merton ^a   Boeckh, Albert ^a   Boothe, Harry ^a   Wilkie, Scott ^a   Jones, Sarah ^a   Finn, Michael ^a   Krohne, Sheryl ^a   Stiles, Jean ^a  

^a Clinical Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANIS FAMILIARIS;

EID: 79251485013     PISSN: 15283593     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Stegemann M, Scheer M: Pharmacokinetics of Baytril® in dogs and cats after oral and parenteral application. Concentrations in serum, skin and saliva. Leverkusen, Germany, Bayer Communications, Bayer AG, 1993.
2. Kung K, Riond JL, Wanner M: Pharmacokinetics of enrofloxacin and its active metabolite ciprofloxacin after intravenous and oral administration of enrofloxacin in dogs. J Vet Pharmacol Ther 16:462-468, 1993.
3. Walker RD, Stein GE, Hauptman G, et al: Pharmacokinetic evaluation of enrofloxacin administered orally to healthy dogs. Am J Vet Res 53:2315-2319, 1992.
4. Monlouis JD, De Jong A, Richez P: Plasma pharmacokinetics and urine concentrations after oral administration of enrofloxacin to dogs. J Vet Pharmacol Ther 20 (suppl 1):61-62, 1997.
5. NCCLS: Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated from Animals: Approved Standards. NCCLS Document M31-A 19(11), Wayne, PA, NCCLS, June 1999.
6. Bergogne-Berezin E: Who or what is the source of antibiotic resistance? J Med Microbiol 46(6):461-464, 1997.
7. Hawkins EC, Boothe DM, Guin A, et al: Concentration of enrofloxacin and its active metabolite in alveolar macrophages and pulmonary epithelial lining fluid of dogs. J Vet Pharmacol Ther 21:18-23, 1998.
8. Pirro F, Scheer M, de Jong A: Additive in vitro activity of enrofloxacin and its main metabolite ciprofloxacin. Proc 14th Annu Congr European Soc Vet Dermatol. Pisa, Italy, September 5-7, 1997.
9. National Academy of Sciences: Guide for the Care and Use of Laboratory Animals. Washington, DC, National Academy Press, 1996.
10. Vogelman B, Gudmundsson S, Leggett J, et al: Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 158:831-847, 1988.
11. Meinen JB, McClure JT, Rosin E: Pharmacokinetics of enrofloxacin in clinically normal dogs and mice and drug pharmacodynamics in neutropenic mice with Escherichia coli and staphylococcal infections. Am J Vet Res 56:1219-1224, 1995.
12. Corvaisier S, Maire PH, Bouvier MY, et al: Comparisons between antimicrobial pharmacodynamic indices and bacterial killing as described by using the Zhi model. Antimicrob Agents Chemother 42:1731-1737, 1998.
13. Dalla Costa T, Derendorf H: AUIC-a general target for the optimization of dosing regimens of antibiotics? Ann Pharmacother 30:1024-1028, 1996.
14. Kung K, Riond JL: Comparison of an HPLC and bioassay method to determine antimicrobial concentrations after intravenous and oral administration of enrofloxacin in four dogs. Res Vet Sci 54:247-248, 1993.
15. Davis JD, Aarons L, Houston JB: Metabolism of theophylline and its inhibition by fluoroquinolones in rat hepatic microsomes. Xenobiotica 25(6):563-573, 1995.
16. Lode H, Borner K, Koeppe P: Pharmacodynamics of fluoroquinolones. Clin Infect Dis 27:33-39, 1998.
17. Lister PD, Sanders CC: Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. J Antimicrob Chemother 43:79-86, 1999.
18. Madaras-Kelly KJ, Larsson AJ, Rotschafer JC: A pharmacodynamic evaluation of ciprofloxacin and ofloxacin against two strains of Pseudomonas aeruginosa. J Antimicrob Chemother 37(4):703-710, 1996.
19. Acar JF, Godstein FW: Trends in bacterial resistance to fluoroquinolones. Clin Infect Dis 24(suppl 1):S67"S73, 1997.
20. Wiedemann B, Grimm H: Susceptibility to antibiotics: Species incidence and trends, in Lorian V (ed): Antibiotics in Laboratory Medicine, ed 4. Baltimore, Williams & Wilkins, 1996, pp 900-1168.
21. Gallicano K, Sahai J: Lack of gender effect on ciprofloxacin pharmacokinetics in humans. Br J Clin Pharmacol 42(5):632-634, 1996.
22. Shah A, Lettieri J, Nix D, et al: Pharmacokinetics of high-dose intravenous ciprofloxacin in young and elderly and in male and female subjects. Antimicrob Agents Chemother 39:1003-1006, 1995.
23. Loi C, Parker BM, Cusack BJ, et al: Aging and drug interactions. III. Individual and combined effects of cimetidine and ciprofloxacin on theophylline metabolism in healthy male and female nonsmokers. J Pharmacol Exp Ther 280:627-637, 1997.
24. Hooper DC: Mechanisms of action and resistance of older and newer fluoroquinolones. Clin Infect Dis 31(suppl 2):S24"S28, 2000.